BioNTech SE (BNTX)
|Net Income (ttm)||18.53M|
|Day's Range||332.40 - 352.99|
|52-Week Range||61.27 - 464.00|
|Price Target||112.62 (-66.2%)|
|Est. Earnings Date||Nov 9, 2021|
BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is involved in the developing of FixVac product candidates, including BNT111, which is in Phase I clinical trial for advance melanoma; BNT112 that is in Phase I/IIa trial for prostate cancer; BNT113, which is in Phase I/II trial to treat HPV+ head and neck cancers; BNT114 that is in Phase I clinical trial for triple negative breast cancer; BNT115 in a Phase I trial in ovarian cancer; and BNT116 for non-small ce... [Read more...]
Financial PerformanceFinancial numbers in millions EURFinancial Statements
According to 10 analysts, the average rating for BioNTech SE stock is "Buy." The 12-month stock price forecast is 112.62, which is a decrease of -66.23% from the latest price.
CDC approves Covid booster shots for those over 65
Anjalee Khemlani joins Yahoo Finance to break down the CDC's decision to support boosters for at-risk workers, vulnerable Americans, and seniors as surges of COVID continue to grip the nation. Don't Mis...
The decision is in line with FDA authorization for booster shots of the Pfizer-BioNTech vaccine.
CDC director overrules advisors, expands booster recommendation
CNBC's Meg Tirrell reports on CDC director overruling advisers to expand Covid vaccine booster recommendation.
Pfizer/BioNTech COVID-19 Boosters For Seniors, Certain Vulnerable Adults Coming Soon - CDC Panel Recommends
The Centers for Disease Control and Prevention (CDC) backed a booster shot of Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for Americans aged 65 and older and adults with an un...
Dr. Rochelle Walensky recommended workers in high-risk settings to also be offered Pfizer Covid booster doses, despite the CDC advisers voting against this group getting the third shot.
Here we highlight some ETFs with high exposure to Pfizer (PFE) that can gain from the encouraging update in coronavirus vaccine.
With its latest ruling on the biotech's coronavirus vaccine, the FDA boosts the investment case for the stock.
CDC advisors vote to recommend Pfizer booster
Meg Tirrell joins Closing Bell with breaking news from a CDC advisory panel evaluating Covid booster shots.
Pfizer recipients 65 and older and those living in long-term care facilities would be eligible for a booster. People ages 18 to 64 with an underlying health condition would be eligible too.
FDA approves Pfizer's (PFE) COVID-19 vaccine booster shots for older adults and high-risk people amid rising infection rates in the country.
The European Medicines Agency (EMA) expects to decide on the authorization for Pfizer Inc (NYSE: PFE) / BioNTech SE (NASDAQ: BNTX) COVID-19 booster shot at the beginning of October, Reuters reported cit...
The U.S. Food and Drug Administration on Wednesday authorized a booster dose of the Pfizer Inc. (NYSE: PFE)-BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine for people aged 65 years and older as well as othe...
FDA Authorizes Pfizer Covid Booster Shots For Seniors And High-Risk Patients — But Not For All Americans
The FDA greenlit a third dose of Pfizer's coronavirus vaccine for seniors, people with underlying health conditions and people with “occupational exposure” to the coronavirus.
The CDC's vaccine advisory committee plans to meet this week, and the agency's panel of experts is expected to vote on plans to distribute third shots.
In the latest trading session, BioNTech SE Sponsored ADR (BNTX) closed at $339.26, marking a -0.61% move from the previous day.
US to donate 500m extra vaccine shots - as Biden tells rich nations to share 'with no strings attached'
The US is buying a further 500 million COVID-19 vaccine doses to donate to other countries, bringing its total commitment to over a billion jabs, President Joe Biden has announced.
Pfizer CEO on providing 500 million vaccines to low income countries
CNBC's "Squawk Box" team discusses the coronavirus vaccine and how it can get to lower income countries to provide equitable access and infrastructure with Pfizer CEO Albert Bourla.
The deal doubles the country's existing commitment and brings the total number of doses it says it will share to 1 billion.
Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) will provide the U.S. government additional 500 million doses of its COVID-19 vaccine. The doses at a not-for-profit price will be used for donation...
Pfizer and BioNTech will provide an additional 500 million doses of their Covid-19 vaccine to the U.S. government to be donated to lower income countries.
Pfizer and BioNTech Expand Collaboration with U.S. to Provide 500 Million Additional COVID-19 Vaccine Doses at Not-Fo...
NEW YORK and MAINZ, Germany, September 22, 2021— Pfizer Inc. (NYSE: PFE, “Pfizer”) and BioNTech SE (Nasdaq: BNTX, “BioNTech”) today announced plans to expand their agreement with the U.S. government by ...
Citing people familiar with the matter, Bloomberg reports that the FDA is expected to decide on Wednesday whether to recommend Pfizer Inc (NYSE: PFE) and BioNTech SE (NASDAQ: BNTX) COVID-19 vaccine as a...
Ultimately, BioNTech's mission is to make treatments that are optimized not only to specific patient needs, but also to time and place.
With recent updates from Pfizer Inc. ( PFE , Financial) and BioNTech SE ( BNTX , Financial) regarding the effectiveness of their Covid-19 vaccine among children ages 5 to 11 and Johnson & Johnson's ( JN...